Atara Biotherapeutics, Inc. (ATRA) Stock Price & Analysis
Atara Biotherapeutics, Inc. (ATRA) fell 3.30% to USD 7.9 as of July 25, 2026 at 04:19 UTC, according to Nexqual real-time market data.
ATRA last closed at USD 8.17; the session ranged USD 7.9–8.35 on volume of 75,089 shares. Market capitalization is $71.18M, with a 52-week range of USD 3.92–19.15 (NMS). Source: Nexqual, July 25, 2026 at 04:19 UTC.
Key Statistics (as of July 25, 2026 at 04:19 UTC)
| Price | USD 7.9 |
|---|---|
| Change | ▼ 3.30% (down) |
| Previous Close | USD 8.17 |
| Open | USD 8.35 |
| Day Range | USD 7.9 – 8.35 |
| 52-Week Range | USD 3.92 – 19.15 |
| Volume | 75,089 shares |
| Market Cap | $71.18M |
| Exchange | NMS |
Technical Analysis (ATRA)
Nexqual's technical model rates ATRA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.11 (neutral) |
| vs SMA50 | Below (USD 9.82) |
| MACD | -0.51 (negative) |
Analyst Ratings (ATRA)
Wall Street analysts rate ATRA "None" based on 3 analysts, with a mean price target of USD 13.67 (range USD 10–18), per Nexqual as of July 25, 2026 at 04:19 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 13.67 |
| High Target | USD 18 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (ATRA)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.25 |
| Revenue Estimate | $366,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.35 vs est -0.1 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.67 ▲ beat |
| 2025-06-30 | USD 0.19 vs est -0.32 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financials & Fundamentals (ATRA)
| Total Revenue | $23.14M |
|---|---|
| Revenue Growth (YoY) | -99.50% |
| Gross Margin | +70.11% |
| Operating Margin | -652.91% |
| Profit Margin | -40.91% |
| Current Ratio | 2.16 |
| Total Cash | $8.36M |
| Total Debt | $10.09M |
| Free Cash Flow | $-17.00M |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financial Health Score (ATRA)
Nexqual rates Atara Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:19 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $8M cash vs $10M debt |
| Cash Flow | Weak — FCF negative: -$17M, burning cash |
| Efficiency | Mixed — No data |
Ownership (ATRA)
| Insider Ownership | +16.92% |
|---|---|
| Institutional Ownership | +52.46% |
| Shares Outstanding | 9.01M |
| Float | 4.66M |
| Short % of Float | +5.72% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Leadership (ATRA)
Atara Biotherapeutics, Inc. is led by Anhco Nguyen (age 52), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:19 UTC.
| President, CEO & Director | Anhco Nguyen (age 52) |
|---|---|
| Interim Chief Financial Officer | Kevin G. Sarney (age 60) |
Major Backers & Investors (ATRA)
Notable institutional backers of Atara Biotherapeutics, Inc. include Adage Capital Partners GP L.L.C., Redmile Group, LLC, Mackenzie Financial Corporation, according to Nexqual as of July 25, 2026 at 04:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adage Capital Partners GP L.L.C. | 7.77% |
| Redmile Group, LLC | 4.9% |
| Mackenzie Financial Corporation | 3.48% |
| Point72 Asset Management, L.P. | 2.16% |
| Acadian Asset Management. LLC | 1.45% |
| EcoR1 Capital, LLC | 1.11% |
| Fidelity | 0.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.81% |
| BlackRock | 1% |
| Geode Capital | 0.73% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
From Atara Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
- Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
- It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.
- The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | USD 1.74 | ▼ 6.45% |
| KYNB | Kyntra Bio, Inc. | USD 7.03 | ▼ 2.56% |
| MGNX | MacroGenics, Inc. | USD 3.7 | ▼ 13.95% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| ANAB | AnaptysBio, Inc. | USD 54.15 | ▲ 2.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:19 UTC. This page is informational and not investment advice.